141 Assessment of thromboembolic risk in mitral stenosis. Is left atrial volume superior to diameter?  by Keenan, Niall et al.
 © Elsevier Masson SAS. All rights reserved.
 
 
46
 
Archives of Cardiovascular Diseases Supplements (2011) 3, 45-54
 
Purpose:
 
 The impact of transcatheter aortic valve implantation (TAVI) on
mitral regurgitation (MR) is controversial. Two recent publications have
reported improvement in MR grades following implantation of the Edwards-
SAPIEN endoprosthesis. These findings were not replicated with the Core-
Valve. The time course of improvement in MR grades with the Edwards-
SAPIEN valve has not been described on an individual patient basis and the
potential mechanisms of benefit are unclear. The aim of this study was to
assess the acute and intermediate changes in MR severity after TAVI with the
Edwards-SAPIEN endoprosthesis 
 
Methods:
 
 Echocardiography was performed in 22 consecutive patients
before and after treatment, and at 1 month follow-up. MR was assessed by
color flow mapping and was graded as none, mild, moderate, or severe. MR
was defined as organic or functional.
 
Results:
 
 The aortic valve area increased from pretreatment 0.72 cm2 to
post-treatment 1.87 cm2 and postdischarge 1.81 cm2 (P<0.0001). Before inter-
vention MR was present in 73% of the patients. It was mild, moderate, or
severe in 36% (n=8), 32% (n=7), and 4% (n=1) respectively. MR was defined
as organic in 6 patients (27%) and functional in 10 patients (45%). Compared
to baseline, MR grades improved by 1 month (p for trend=0.01). This benefit
was secondary to a reduction in regurgitation grades in 50% of patients with
an MR at baseline (n=6), while no worsening was observed in the other
patients with an MR (n=6) and no occurrence of MR was observed in patients
without MR (n=6). A trend for a greater improvement in MR grade was
observed in patients with functional MR (n=7, - 1.00) compared to those with
an organic MR (n=5, - 0.294; p=0.10).
 
Conclusion:
 
 In consecutive patients with a successful implantation of an
Edwards-SAPIEN valve a significant improvement in MR was observed. This
benefit was secondary to an improvement in 50% of patients with an MR and
no worsening in the others. 
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Objective: 
 
In patients with mitral stenosis (MS) in sinus rhythm (SR)
without thromboembolic complications, current guidelines recommend antico-
agulation if the left atrium (LA) is enlarged based on M-mode diameter. How-
ever, LA diameter poorly reflects LA enlargement. The aim of this study was
to compare the predictive value of LA diameter and volume for the risk of
embolic events as assessed by LA appendage emptying velocity (LAAv)
<25cm/s and dense LA spontaneous contrast (SEC) during transesophageal
echocardiography (TEE).
 
Methods: 
 
152 patients (53±14years,73% female) with severe MS (valve
area <1.5cm
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) were prospectively enrolled. A subset of 80 patients were iden-
tified in SR who also underwent clinically indicated TEE.
 
Results: 
 
Mean LA diameter and LA volume were significantly correlated
(50±7[32-77]mm vs. 152±70[67-720]ml,(r=0.71,p<0.001) but the relation was
curvilinear and the 95% CI increased with LA diameter. In the SR/TEE subset,
LA diameter was not significantly different between patients with normal vs.
low LAAv (50±6 vs. 48±6mm,p=0.13) or between those with dense SEC vs.
no/mild SEC (49±6 vs. 46±5mm,p=0.11). In contrast body surface area
(BSA)-indexed LA volume differentiated patients with normal vs. low LAAv
(86±17 vs. 71±17 ml/m
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,p<0.01) and patients with dense SEC vs. no/mild
SEC (81±16 vs. 63±15 ml/m
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, p<0.01). BSA-indexed LA volume provided the
highest area under the curve (AUC)(0.85) for high thromboembolic risk and
LA diameter the lowest (0.65). A BSA-indexed LA volume above 60 ml/m
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provided an excellent 90% sensitivity despite 44% specificity, 76% positive
predictive value and 70% negative predictive value.
 
Conclusions: 
 
LA diameter is a poor indicator of LA size, with a range of
error which is wide. In patients with MS in SR, LA volume is a better pre-
dictor of thromboembolic risk. We suggest using BSA-indexed LA volume to
guide anticoagulation decisions and with a threshold of 60 ml/m
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 which has a
good sensitivity albeit with a low specificity.
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Purpose:
 
 To describe the impact of coronary artery disease (CAD) on
management of high-risk patients with aortic stenosis referred for transcatheter
aortic valve implantation (TAVI). 
Methods: Of 240 patients referred for TAVI, 145 (60%) effectively underwent
TAVI, while 31 (13%) were re oriented towards conventional surgery and 64
(27%) were conservatively managed. We compared the 147 patients (61%)
with CAD with the 93 (39%) with no CAD. 
 
Results:
 
 Patients with CAD presented with one or several of the following:
previous myocardial infarction in 54 (37%), coronary artery bypass grafting
(CABG) in 63 (43%), percutaneous coronary intervention (PCI) in 49 (33%).
CAD was diagnosed during the screening for TAVI in 46 (31%). CAD led to
re orient 5 patients (2%) towards conventional surgery for combined aortic
valve replacement and CABG, and to perform PCI before TAVI in 9 (6%) or
during the procedure in 2 (1%). No patient was denied any intervention
because of CAD. The comparison between patients with and without CAD is
detailed in the Table. 
 
Conclusions: 
 
In high-risk patients referred for TAVI, CAD is frequent and
associated with worse baseline characteristics, but has a limited impact on
indications for TAVI. It seldom requires associated revascularisation and has
no impact on mid-term results of TAVI.   
 Overall (n=240) CAD (n=147) no CAD (n=93) p
Age (years) 81±8 81±9 83±7 0.07
Female gender 111 (46%) 47 (32%) 64 (69%) <0.0001
Carotid artery disease 58 (24%) 50 (34%) 8 (9%) <0.0001
Renal failure 89 (37%) 63 (43%) 26 (28%) 0.03
 2 comorbidities 151 (63%) 104 (71%) 47 (50%) 0.002
EuroSCORE (%) 28±16 31±17 24±12 0.001
TAVI performed 145 (60%) 83 (56%) 62 (67%) 0.11
TAVI procedural success 141 (97%) 81 (98%) 60 (97%) 0.76
post-TAVI troponin (mcg/L) 4.5±0.6 5.2±0.7 3.5±0.9 0.07
30-day post TAVI survival (%) 88 91 85 0.25
1-year post TAVI survival (%) 74±4 76±5 71±7 0.36
NYHA I/II last follow-up (%) 85 85 85 0.73
